Drugmaker AbbVie is expected to report Friday that it is not only paying a $1.6 billion break-up fee for terminating the year’s biggest merger but a currency hit related to the deal as well.

AbbVie and Shire this month terminated a $55 billion merger due to new US Treasury rules limiting tax inversions benefits as well as the mega-fee.

What’s more, AbbVie is expected to report a more than $500 million currency hit on the cash it expected to use for the merger, several AbbVie investors said.

The dollar has risen by about 8 percent since the July merger announcement.

Chicago-based AbbVie has more than $5 billion in cash overseas, and was expected to use much of it to fund the $25 billion cash portion of its Shire deal.

Now, it has announced it will use $5 billion to fund a stock-repurchase program.

Meanwhile, at least one AbbVie investor has told the UK Takeover Panel that AbbVie was reassuring hedge funds that the Shire deal was going through during a time it was restricted from speaking about the merger, a source said.